THE SOLUTION. The proposed reform was initially developed by the National Coordinating Committee for Multiemployer Plans. Representing both labor and management, the organization proposed allowing troubled plans to take action to save themselves. Education and the Workforce Committee Chairman Xxxx Xxxxx (R-MN) and senior Democrat Xxxxxx Xxxxxx (D-CA) have announced bipartisan multiemployer pension reform legislation that mirrors this proposal, which is backed by business and labor leaders and known as “Solutions, Not Bailouts.” It is the only available option that could save these failing plans, and it is the last chance that labor unions and their members have to gain some control over the future of their pensions. This reform would give multiemployer pension plans the tools they need to rescue themselves. The bipartisan agreement would provide the critical flexibility necessary to keep pension plans from going under and causing workers to lose everything. The proposal includes reforms to protect taxpayers and provide trustees with new tools to save troubled plans. It also includes important consumer safeguards to give participants in these plans a voice and to protect the most vulnerable retirees. Specifically, the bipartisan reform will: Permit trustees of severely underfunded plans to adjust vested benefits, enabling deeply troubled plans to survive without a federal bailout. Require approval by plan participants of any proposed benefit adjustments that take effect. This provision includes a fail-safe mechanism for those plans that present a systemic risk the multiemployer pension system. Provide participant protections to safeguard the most vulnerable retirees, including disabled retirees and individuals age 75 and older. Give the PBGC the authority to take earlier action to help save failing plans, reducing potential future costs.
THE SOLUTION. How did you find a solution? ● What CCS framework was used and how did it work? ● How did the CCS service/product help you to get over the challenge and solve the problem? ● How did you find the process? With CCS? With the supplier?
THE SOLUTION. McGraw Hill has developed a web-based solution (the "Solution") that enables users to access certain online products and services ("Services") and related courses, content and information (together with the Services, the "McGraw Hill Content") offered by McGraw Hill through our website (the "Website") by purchasing a subscription. McGraw Hill hereby grants Subscriber a non-exclusive, non-transferable license to access and use the Solution, and allow each administrator, faculty member, and student enrolled by Subscriber (each a designated "End User") to access and use the Solution, through the Website, solely for educational purposes. End Users may access the Solution and the McGraw Hill Content in accordance with an access method offered by McGraw Hill and selected by Subscriber. All End Users other than K-12 students will be required to agree to the Terms of Use in order to access the Solution and the McGraw Hill Content. Payments of applicable fees to McGraw Hill are due within thirty (30) days of the date of invoice unless otherwise agreed to in writing.
THE SOLUTION establishment of the Paragraph 6 System This problem was recognized in Paragraph 6 of the Declaration (hence the reference to the ‘Paragraph 6 System’). Subsequent work in the TRIPS Council prepared the ground for the adoption of two important General Council decisions establishing the Paragraph 6 System, which were both adopted in the light of a Chairman’s statement setting out several key shared understandings of Members on how the Paragraph 6 System would be interpreted and implemented. These two decisions are provided in Annexes 7 and 8. The General Council Decision of 30 August 2003 on the Implementa- tion of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health (WT/L/540 and Corr.1) waives under certain circumstances
THE SOLUTION. Uniform legislation A federal or state uniform legislation regarding medical malpractice arbitration agreements should be enacted to avoid judicial inconsistencies and promote such agreements. Clauses based on the following suggestions should be included in any uniform statute in order to safeguard both patients and physicians.
THE SOLUTION. ELSEVIER has developed a web-based service delivery environment that enables Institution and its Sites to access certain online content products and services offered by ELSEVIER (the (the "Linking Solution"). . Institution and its Sites hereby wish to use the Linking Solution, which may include personalized access to content to integrate with Institution and/or Sites's learning management system ("LMS"). Site(s) may have procured Products to be utilized in connection with the LMS via Linking Solution. Any procurement of such Products to be provided by ELSEVIER to Sites shall be set forth in a separate purchasing agreement between ELSEVIER and such Site(s).
THE SOLUTION. 3.1. Each year on the anniversary of the Effective Date, the Licensor will provide the Reseller with the Price List for the forthcoming 12 (twelve) month period. The Price List may be revised from time to time by Agreement between the Parties. If the Master Licensor amends its price list for the Software to the Licensor, the Licensor may amend the Price List by giving the Reseller 30 (thirty) days written notice.
THE SOLUTION. Contractor shall use its Solution to provide Services including but not limited to Operations at Contractor’s Sites in accordance with the Contract.
THE SOLUTION. The issues mentioned above could be resolved by the use of standardised templates. Since APIC is committed to improve the relationship between the different stakeholders in the production process of safe API, APIC has developed this Quality Agreement Guideline including the corresponding templates. The APIC Task Force that did the work consisted of members from both specialised API/intermediate manufacturers and companies primarily making finished drug products. Hence APIC believes that the result represents best industry practice considering the needs and requirements that enter into such a Quality Agreement.
THE SOLUTION. The highlight of the CCID partnership was the development of a continuous crystallization process for a Pfizer API, using an Xxx- L i l l y lab scale 2 - pot MSMPR crystallization r ig, and subsequent scale up of the crystallization to 2 20 L crystallizers and i solation on a high frequency f i l ter ( HFF) in the Pfizer KTL facility in Ringaskiddy, with a successful 95 - hour continuous crystallization run. THE IMPACT The UL crystallisation process was successfully scaled up at the K i lo Technology Laboratory ( KTL, Cork) in Pfizerby Pfizer technical staff following a technology handover. The UL researchers supported the demonstrations and Xxx X x x x x researchers were also in attendance, this in i tself i s a f i rst for I r i sh academia and testament to the potential value realized in this work. The KTL also successful demonstrated the continuous i solation of API by integrating the high frequency f i l ter to the continuous crystalliser, generating 10 kg of API per 24 - hour period. CCID also leverage existing administration support structures within the SSPC, existing as an SSPC – associated project, and took advantage of existing SSPC procedures in relation to industrialinteractions, Intellectual Property Management and Heads of Agreement. The CCIDpartnership significantly enhanced the in- house expertise in continuous downstream processing in Pfizer and Xxx- L i l l y . The skill- set developed in continuous manufacturing within Pfizer and Xxx X x x x x will differentiate the I r i sh manufacturing base within the respective company parent networks. Since commencing this partnership project both I r i sh manufacturing bases have received significant investment from their US based parent company for continuous process development, and capital investment in continuous manufacturing. L i l l y and Pfizer locally continue to consult with each other on new developments in this technology space. Continuous i solation and drying will continue to be investigated by SSPC through phase I I of i ts funding period ( 2019 – 2025 ) . “ For Pfizer, two results were achieved with th i s project, one been the successful running of the crystallisation and i solation for a fu l l working week, and secondly the partnerships and relationships forged within Pfizer Cork, Singapore and US and also between L i l l y Cork, L i l l y US and UL, without them we wouldn’ t have achieved the milestones of the project.”